Stock Events

Stock Events

Adial Pharmaceuticals 

$6.80
65
+$0.13+2.03% 18:28 Today

Statistics

Day High
7
Day Low
6.27
52W High
10.75
52W Low
1.31
Volume
15,117
Avg. Volume
414,671
Mkt Cap
19.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-11.25
-7.56
-3.87
-0.18
Expected EPS
-0.175
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.98MNet Income

Analyst Ratings

6.00Average Price Target
The highest estimate is 6.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADIL. It's not an investment recommendation.
Amazon
7
AMZN
Alphabet
7
GOOGL
NVIDIA
6
NVDA
Palantir Technologies
6
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc focuses on central nervous system (CNS) diseases, including addiction, which competes with Adial's focus on addiction treatments.
Indivior Pharmaceuticals
INDV
Mkt Cap4.79B
Indivior PLC offers products for the treatment of opioid dependence, directly competing with Adial's addiction treatment portfolio.
Opko Health
OPK
Mkt Cap1.1B
OPKO Health, Inc. has a diverse portfolio, including pharmaceuticals for addiction, making it a competitor in the addiction treatment market.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals Inc. focuses on CNS disorders, a market that overlaps with Adial's addiction and alcohol use disorder treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing in the broader pharmaceutical market.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.87B
Jazz Pharmaceuticals plc has a portfolio that includes CNS treatments, competing in the same therapeutic area as Adial.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.54B
Supernus Pharmaceuticals, Inc. focuses on developing and commercializing products for the treatment of CNS diseases, overlapping with Adial's market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including CNS and addiction treatments, making it a broad competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated is involved in creating transformative medicines for people with serious diseases, potentially competing in innovation and market share.

About

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
Show more...
CEO
Cary John Claiborne
Employees
6
Country
United States
ISIN
US00688A3041

Listings

XNAS
US
ADIL
BOATS
BOATS
ADIL.BOATS

0 Comments

Share your thoughts

FAQ

What is Adial Pharmaceuticals stock price today?▼
The current price of ADIL is $6.80 USD — it has increased by +2.03% in the past 24 hours. Watch Adial Pharmaceuticals stock price performance more closely on the chart.
What is Adial Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adial Pharmaceuticals stocks are traded under the ticker ADIL.
Is Adial Pharmaceuticals stock price growing?▼
ADIL stock has risen by +21.61% compared to the previous week, the month change is a +79.21% rise, over the last year Adial Pharmaceuticals has showed a -22.17% decrease.
What is Adial Pharmaceuticals market cap?▼
Today Adial Pharmaceuticals has the market capitalization of 19.93M
When is the next Adial Pharmaceuticals earnings date?▼
Adial Pharmaceuticals is going to release the next earnings report on November 18, 2026.
What were Adial Pharmaceuticals earnings last quarter?▼
ADIL earnings for the last quarter are -11.25 USD per share, whereas the estimation was -1.03 USD resulting in a -989.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adial Pharmaceuticals revenue for the last year?▼
Adial Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Adial Pharmaceuticals net income for the last year?▼
ADIL net income for the last year is -7.98M USD.
How many employees does Adial Pharmaceuticals have?▼
As of September 04, 2026, the company has 6 employees.
In which sector is Adial Pharmaceuticals located?▼
Adial Pharmaceuticals operates in the Health & Wellness sector.
When did Adial Pharmaceuticals complete a stock split?▼
The last stock split for Adial Pharmaceuticals was on February 06, 2026 with a ratio of 1:25.
Where is Adial Pharmaceuticals headquartered?▼
Adial Pharmaceuticals is headquartered in CHARLOTTESVILLE, United States.